Characterization and management of gastrointestinal (Gi) adverse events (Aes) with zanidatamab + chemotherapy (Ct) ± tislelizumab in first-line (1l) HER2-positive (Her2+) locally advanced or metastatic gastroesophageal adenocarcinoma (Mgea): Analysis from HERIZON-GEA-01

by biblioteca on 19 d'octubre de 2026 with No hi ha comentaris

Elimova, E., Rha, S. Y., Shitara, K., Liu, T., Tabernero, J., Lee, K.-W., Schenker, M., Tebbutt, N. C., Ajani, J. A., Salimin, N., Ku, G. Y., Kim, J. G., Diaz, I. A., Zhang, J., Pietrantonio, F., Bai, L.-Y., Le Sourd, S., Chen, Y., Grim, J. E., & Shen, L. (2026). Characterization and management of gastrointestinal (Gi) adverse events (Aes) with zanidatamab + chemotherapy (Ct) ± tislelizumab in first-line (1l) HER2-positive (Her2+) locally advanced or metastatic gastroesophageal adenocarcinoma (Mgea): Analysis from HERIZON-GEA-01. Journal of Clinical Oncology, 44(16_suppl), 4042-4042. https://doi.org/10.1200/JCO.2026.44.16_suppl.4042 (Meeting abstract)